本帖最后由 老马 于 2012-1-13 21:20 编辑
4 s) u# z( w5 I& ~" v. [
# M6 F) N( l# W3 g& O爱必妥和阿瓦斯丁的比较' }* d n5 {# r* W
T6 d7 q2 w8 q$ h3 `5 Q0 n+ m$ phttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
; j: e' e a. z. c5 L; l) s) I0 L
5 X# i7 O: }8 @( C ^
% c+ g b6 [! L3 }: J v
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
; ~6 Y5 Z1 V9 h3 \4 {' V5 j ~==================================================- }" `0 Y3 w7 g/ T
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)1 T* y' K/ ^( q( T: y1 a
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
% U7 v3 u! h) Q. X" n, J$ IResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.' L) X5 Q/ g: n
|
显身卡
